clonoSEQ receives FDA clearance for the detection and monitoring of measurable residual disease (MRD) in patients with multiple myeloma and acute lymphoblastic leukemia.
clonoSEQ receives FDA clearance for the detection and monitoring of measurable residual disease (MRD) in patients with multiple myeloma and acute lymphoblastic leukemia.